Literature DB >> 10843404

Colorectal cancer chemoprevention: aspirin, other NSAID and COX-2 inhibitors.

G A Kune1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843404     DOI: 10.1046/j.1440-1622.2000.01844.x

Source DB:  PubMed          Journal:  Aust N Z J Surg        ISSN: 0004-8682


× No keyword cloud information.
  7 in total

1.  JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.

Authors:  Martha L Slattery; Abbie Lundgreen; Susan A Kadlubar; Kristina L Bondurant; Roger K Wolff
Journal:  Mol Carcinog       Date:  2011-11-28       Impact factor: 4.784

2.  Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival.

Authors:  Martha L Slattery; Abbie Lundgreen; Kristina L Bondurant; Roger K Wolff
Journal:  Carcinogenesis       Date:  2011-08-22       Impact factor: 4.944

3.  Effects of consumption of whole grape powder on basal NF-κB signaling and inflammatory cytokine secretion in a mouse model of inflammation.

Authors:  Sonni-Ali Miller; Jason A White; Rupak Chowdhury; Dominique N Gales; Berhanu Tameru; Amit K Tiwari; Temesgen Samuel
Journal:  J Nutr Intermed Metab       Date:  2017-11-22

4.  Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2.

Authors:  Dong-Sheng Huang; Ke-Zhen Shen; Jian-Feng Wei; Ting-Bo Liang; Shu-Sen Zheng; Hai-Yang Xie
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

5.  Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs.

Authors:  Temesgen Samuel; Khalda Fadlalla; Dominique N Gales; Balananda D K Putcha; Upender Manne
Journal:  BMC Cancer       Date:  2014-08-18       Impact factor: 4.430

6.  Inhibition of PGE2/EP4 receptor signaling enhances oxaliplatin efficacy in resistant colon cancer cells through modulation of oxidative stress.

Authors:  Huakang Huang; Oladimeji Aladelokun; Takayasu Ideta; Charles Giardina; Lee M Ellis; Daniel W Rosenberg
Journal:  Sci Rep       Date:  2019-03-20       Impact factor: 4.379

7.  Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells.

Authors:  Yun Wang; Long Cui; Peter Georgiev; Latika Singh; Yanyan Zheng; Ying Yu; Jeff Grein; Chunsheng Zhang; Eric S Muise; David L Sloman; Heidi Ferguson; Hongshi Yu; Cristina St Pierre; Pranal J Dakle; Vincenzo Pucci; James Baker; Andrey Loboda; Doug Linn; Christopher Brynczka; Doug Wilson; Brian B Haines; Brian Long; Richard Wnek; Svetlana Sadekova; Michael Rosenzweig; Andrew Haidle; Yongxin Han; Sheila H Ranganath
Journal:  Oncoimmunology       Date:  2021-03-18       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.